Trillium Therapeutics (NASDAQ: TRIL) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Institutional & Insider Ownership

48.0% of Trillium Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Trillium Therapeutics and SIGA Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trillium Therapeutics N/A -178.08% -61.40%
SIGA Technologies -175.90% N/A -18.99%

Valuation & Earnings

This table compares Trillium Therapeutics and SIGA Technologies’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Trillium Therapeutics N/A N/A -$28.62 million ($3.73) -1.98
SIGA Technologies $21.28 million 12.60 -$18.34 million N/A N/A

SIGA Technologies has higher revenue and earnings than Trillium Therapeutics.

Analyst Ratings

This is a summary of current recommendations for Trillium Therapeutics and SIGA Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trillium Therapeutics 0 0 5 0 3.00
SIGA Technologies 0 0 0 0 N/A

Trillium Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 102.70%. Given Trillium Therapeutics’ higher possible upside, research analysts clearly believe Trillium Therapeutics is more favorable than SIGA Technologies.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

SIGA Technologies Company Profile

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.